Injectable drug delivery offers a promising alternative for the delivery of drugs that are ineffective when administered orally. Injectable drug delivery is aimed to maximize patient compliance and reduce the frequency of dosage administration without compromising the effectiveness of the treatment.
The major factors responsible for the growth of the European injectable drug delivery market are the rising prevalence of chronic diseases, growth of the biologics market, rising demand for self-injection devices, and technological advancements. Owing to these factors, the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes is increasing. On the other hand, alternative methods such as oral and transdermal delivery, safety concerns, and risk of blood-borne infections are expected to restrain the growth of this market.
The European injectable drug delivery market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. Based on type, the European injectable drug delivery market is segmented into devices and formulations. The devices market is further segmented into conventional injection devices, self-injections, and other devices. The formulations market is further segmented into conventional drug delivery formulations, novel drug delivery formulations, and long-acting injection formulations.
On the basis of therapeutic application, the European injectable drug delivery market is segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other diseases. On the basis of usage pattern, the market is segmented into curative care, immunization, and others.
On the basis of mode of administration, the European injectable drug delivery market is segmented into skin, organs, central nervous system, and circulatory/musculoskeletal system. On the basis of end user, the market is segmented into hospitals/clinics, home care setting, research laboratories, pharma and biotech companies, and other end users.
Key players in the European injectable drug delivery market include Becton, Dickinson and Company (U.S.), Baxter International, Inc. (U.S.), Gerresheimer AG (Germany), Pfizer, Inc. (U.S.), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and Eli Lilly and Company (U.S.).